Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Summary

This phase II trial studies the side effects of talabostat and pembrolizumab and to see how well they work for the treatment of solid cancers that have spread to other places in the body (advanced). Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talabostat and pembrolizumab may help control the disease.

Timeline

Start

2020-03-19

Primary completion

2025-03-11

Completion

2025-03-11

Outcome

Outcome not reported

Stopped: “There is no PR/CR observed in the first stage, so study stopped without proceeding to the stage 2 of efficacy stage.”

Drugs

Indications